# Sarepta Therapeutics, Inc.: overview

SRPT · Nasdaq · CIK 873303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srpt.md) · [Financials](/companies/srpt/financials.md) · [Filings](/companies/srpt/filings.md) · [Insiders](/companies/srpt/insiders.md)

Latest reported revenue: [$328.7m](/filings/0001193125-26-335003.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335003).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [430](/filings/0001193125-25-269436.md) | [658](/filings/0001193125-26-084144.md) | [612](/filings/0001193125-26-208893.md) | [513](/filings/0001193125-26-335003.md) | [370](/filings/0001193125-25-269436.md) | [443](/filings/0001193125-26-084144.md) | [331](/filings/0001193125-26-208893.md) | [329](/filings/0001193125-26-335003.md) |
| Gross margin | % | [78.7%](/filings/0001193125-26-084144.md) | [76.8%](/filings/0001193125-26-084144.md) | [77.5%](/filings/0001193125-26-084144.md) | [70.3%](/filings/0001193125-26-084144.md) | [59.3%](/filings/0001193125-26-084144.md) | [(6.6%)](/filings/0001193125-26-084144.md) | not reported | not reported |
| Operating margin | % | [5.2%](/filings/0001193125-25-269436.md) | [24.6% d](/filings/0001193125-26-084144.md) | [(49.1%)](/filings/0001193125-26-208893.md) | [22.5%](/filings/0001193125-26-335003.md) | [(27.9%)](/filings/0001193125-25-269436.md) | [(92.9%) d](/filings/0001193125-26-084144.md) | [108.4%](/filings/0001193125-26-208893.md) | [4.0%](/filings/0001193125-26-335003.md) |
| Net margin | % | [7.8%](/filings/0001193125-26-084144.md) | [24.2%](/filings/0001193125-26-084144.md) | [(73.2%)](/filings/0001193125-26-335003.md) | [38.4%](/filings/0001193125-26-335003.md) | [(13.7%)](/filings/0001193125-26-084144.md) | [(93.1%)](/filings/0001193125-26-084144.md) | [100.1%](/filings/0001193125-26-335003.md) | [(1.5%)](/filings/0001193125-26-335003.md) |
| Diluted EPS | $ per share | [0.34](/filings/0001193125-26-084144.md) | [1.50](/filings/0001193125-26-084144.md) | [(4.60)](/filings/0001193125-26-208893.md) | [1.89](/filings/0001193125-26-335003.md) | [(0.50)](/filings/0001193125-26-084144.md) | [(3.93)](/filings/0001193125-26-084144.md) | [2.88](/filings/0001193125-26-208893.md) | [(0.05)](/filings/0001193125-26-335003.md) |
| Free cash flow | $m | [(108) d](/filings/0001193125-25-269436.md) | [54.0 d](/filings/0001193125-26-084144.md) | [(627)](/filings/0001193125-26-208893.md) | [230 d](/filings/0001193125-26-335003.md) | [(37.5) d](/filings/0001193125-25-269436.md) | [128 d](/filings/0001193125-26-084144.md) | [(205)](/filings/0001193125-26-208893.md) | [197 d](/filings/0001193125-26-335003.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [612](/filings/0000950170-24-022036.md) | [844](/filings/0000950170-25-029973.md) | [1,145](/filings/0001193125-26-084144.md) | [1,788](/filings/0001193125-26-084144.md) | [1,864](/filings/0001193125-26-084144.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(75.1%)](/filings/0000950170-24-022036.md) | [(63.5%)](/filings/0000950170-25-029973.md) | [(23.4%)](/filings/0001193125-26-084144.md) | [12.2%](/filings/0001193125-26-084144.md) | [(37.5%)](/filings/0001193125-26-084144.md) |
| Net margin | % | [(68.4%)](/filings/0000950170-24-022036.md) | [(83.4%)](/filings/0000950170-25-029973.md) | [(46.8%)](/filings/0001193125-26-084144.md) | [13.2%](/filings/0001193125-26-084144.md) | [(38.3%)](/filings/0001193125-26-084144.md) |
| Diluted EPS | $ per share | [(5.15)](/filings/0000950170-24-022036.md) | [(8.03)](/filings/0000950170-25-029973.md) | [(5.80)](/filings/0001193125-26-084144.md) | [2.34](/filings/0001193125-26-084144.md) | [(7.13)](/filings/0001193125-26-084144.md) |
| Free cash flow | $m | [(482)](/filings/0000950170-24-022036.md) | [(356)](/filings/0000950170-25-029973.md) | [(577)](/filings/0001193125-26-084144.md) | [(343)](/filings/0001193125-26-084144.md) | [(307)](/filings/0001193125-26-084144.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/srpt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $341.3m | 18,994,958 |  | Added +4,239,681 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $160.2m | 8,916,090 |  | Added +2,302,776 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $150.5m | 8,377,470 |  | Added +1,736,778 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $82.6m | 4,598,735 |  | Added +5,540 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $82.5m | 4,591,755 |  | Added +13,520 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $78.5m | 4,365,951 |  | Added +230,163 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $76.9m | 4,325,689 |  | Reduced −2,107,423 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $49.8m | 2,771,758 |  | Added +782,962 |
| [Erste Asset Management GmbH](/funds/2024532.md) | 2026-06-30 | $45.5m | 2,568,945 |  | Reduced −400,000 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $39.6m | 2,206,022 |  | Added +1,480,954 |

## Recent filings

[All 1,169 filings](/companies/srpt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:06 ET | [8-K](/filings/0001193125-26-335056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335056 |
| 2026-08-05 | 16:01 ET | [10-Q](/filings/0001193125-26-335003.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335003 |
| 2026-07-27 | 09:08 ET | [8-K](/filings/0001193125-26-316995.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-316995 |
| 2026-06-04 | 16:29 ET | [8-K](/filings/0001193125-26-257501.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257501 |
| 2026-05-06 | 16:10 ET | [8-K](/filings/0001193125-26-208966.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208966 |
| 2026-05-06 | 16:01 ET | [10-Q](/filings/0001193125-26-208893.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208893 |
| 2026-04-24 | 16:10 ET | [DEF 14A](/filings/0001193125-26-177247.md) | Proxy statement, period 2026-06-04 | 0001193125-26-177247 |
| 2026-03-02 | 07:02 ET | [10-K](/filings/0001193125-26-084144.md) | Annual report, period 2025-12-31 | 0001193125-26-084144 |
| 2026-02-25 | 17:09 ET | [8-K](/filings/0001193125-26-072064.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-072064 |
| 2026-02-25 | 16:10 ET | [8-K](/filings/0001193125-26-071566.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071566 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-084144.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cacec732-ac25-4255-a045-4f59c6c75fbd)

## About the filer

- CIK: 873303
- Tickers: SRPT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.